Brain hypothermic therapy dramatically decreases elevated blood concentrations of high mobility group box 1 in

Toshihiko Nakamura1, Shingo Yamada, Toshirou Yoshioka

  • 1National Hospital Organization, Nishisaitama-Chuo National Hospital, Japan.

Disease Markers
|November 6, 2013
PubMed

Insights

Brain hypothermic therapy (BHT) significantly reduces high mobility group box 1 (HMGB1) levels in neonates with hypoxic-ischemic encephalopathy (HIE). HMGB1 serves as a key indicator for inhibiting early-stage inflammation following BHT.

Area of Science:

  • Neonatal Medicine
  • Neurology
  • Biochemistry

Background:

  • Hypoxic-ischemic encephalopathy (HIE) in neonates often requires brain hypothermic therapy (BHT) as per ILCOR Consensus 2010.
  • High mobility group box 1 (HMGB1) elevation is implicated in inflammatory cytokine release during early brain ischemia-reperfusion injury.

Purpose of the Study:

  • To investigate the impact of BHT on HMGB1 levels in neonates with HIE.
  • To assess HMGB1 as a potential biomarker for early inflammation inhibition.

Main Methods:

  • Plasma HMGB1 concentrations were measured in 21 neonates.
  • Groups included: 8 neonates with HIE undergoing BHT (BHT+), 5 neonates with HIE not receiving BHT (BHT-), and 8 normal controls.

Main Results:

  • Umbilical artery HMGB1 (UA-HMGB1) levels were significantly elevated before BHT in the BHT+ group.
  • UA-HMGB1 levels in the BHT- group were not significantly different from reference values initially but increased 24 hours post-birth.
  • Repeated measure ANOVA revealed significant differences in time-course changes between BHT+ and BHT- groups (P = 0.0002).

Conclusions:

  • Brain hypothermic therapy effectively decreases HMGB1 levels in neonates with HIE.
  • HMGB1 is a valuable biomarker for monitoring the inhibition of early-stage inflammation in neonatal brain injury.
Abstract